Neuroinflammation mediated by IL-1β increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson's disease

The rat brain in stereotaxic coordinates

Palkovits, M. (1983) · Neuropeptides · doi:10.1016/0143-4179(83)90049-5 · Cited by 28,959 · see citing works

The Rat Brain in Stereotaxic Coordinates

Paxinos, G., & Watson, C. (1983) · Elsevier eBooks · doi:10.1016/c2009-0-63235-9 · Cited by 28,585 · see citing works

Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease

Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240 · see citing works

Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism

Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227 · see citing works

Microglia: a sensor for pathological events in the CNS

Kreutzberg, G. W. (1996) · Trends in Neurosciences · doi:10.1016/0166-2236(96)10049-7 · Cited by 4,396 · see citing works

Hereditary Early-Onset Parkinson's Disease Caused by Mutations in <i>PINK1</i>

Valente, E. M., Abou-Sleiman, P. M., Caputo, V., Muqit, M. M. K., Harvey, K., Gispert, S., Ali, Z., Del Turco, D., Bentivoglio, A. R., Healy, D. G., et al. (2004) · Science · doi:10.1126/science.1096284 · Cited by 3,481 · see citing works

Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology

Zimprich, A. A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M. J., Lincoln, S., Kachergus, J. M., Hulihan, M., Uitti, R. J., Calne, D. B., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.11.005 · Cited by 3,024 · see citing works

Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator

West, M. J., Slomianka, L., & Gundersen, H. J. G. (1991) · The Anatomical Record · doi:10.1002/ar.1092310411 · Cited by 2,994 · see citing works

Reactive microglia are positive for HLA‐DR in the substantia nigra of Parkinson's and Alzheimer's disease brains

McGeer, P. L., Itagaki, S., Boyes, B. E., & McGeer, E. G. (1988) · Neurology · doi:10.1212/wnl.38.8.1285 · Cited by 2,990 · see citing works

Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism

Bonifati, V., Rizzu, P., van Baren, M. J., Schaap, O., Breedveld, G. J., Krieger, E., Dekker, M. C. J., Squitieri, F., Ibáñez, P., Joosse, M., et al. (2003) · Science · doi:10.1126/science.1077209 · Cited by 2,800 · see citing works

Systemic LPS causes chronic neuroinflammation and progressive neurodegeneration

Qin, L., Wu, X., Block, M. L., Liu, Y., Breese, G. R., Hong, J., Knapp, D. J., & Crews, F. T. (2007) · Glia · doi:10.1002/glia.20467 · Cited by 2,144 · see citing works

Cytokines and acute neurodegeneration

Allan, S. M., & Rothwell, N. J. (2001) · Nature reviews. Neuroscience · doi:10.1038/35094583 · Cited by 1,126 · see citing works

Activation of innate immunity in the CNS triggers neurodegeneration through a Toll-like receptor 4-dependent pathway

Lehnardt, S., Massillon, L., Follett, P., Jensen, F. E., Ratan, R., Rosenberg, P. A., Volpe, J. J., & Vartanian, T. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1432609100 · Cited by 1,052 · see citing works

Tumor necrosis factor and interleukin-1 lead to phosphorylation and loss of I kappa B alpha: a mechanism for NF-kappa B activation.

Beg, A. A., Finco, T. S., Nantermet, P. V., & Baldwin, A. S. (1993) · Molecular and Cellular Biology · doi:10.1128/mcb.13.6.3301 · Cited by 1,027 · see citing works

Regional Difference in Susceptibility to Lipopolysaccharide-Induced Neurotoxicity in the Rat Brain: Role of Microglia

Kim, W., Mohney, R. P., Wilson, B. C., Jeohn, G., Liu, B., & Hong, J. (2000) · Journal of Neuroscience · doi:10.1523/jneurosci.20-16-06309.2000 · Cited by 881 · see citing works

Parkinson Disease in Twins

Tanner, C. M., Ottman, R., Goldman, S. M., Ellenberg, J., Chan, P., Mayeux, R. P., & Langston, J. W. (1999) · JAMA · doi:10.1001/jama.281.4.341 · Cited by 869 · see citing works

Interleukin-1β, interleukin-6, epidermal growth factor and transforming growth factor-α are elevated in the brain from parkinsonian patients

Mogi, M., Harada, M., Kondo, T., Riederer, P., Inagaki, H., Minami, M., & Nagatsu, T. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90508-8 · Cited by 855 · see citing works

Progressive degeneration of nigrostriatal dopamine neurons following intrastriatal terminal lesions with 6-hydroxydopamine: A combined retrograde tracing and immunocytochemical study in the rat

Sauer, H., & Oertel, W. H. (1994) · Neuroscience · doi:10.1016/0306-4522(94)90605-x · Cited by 807 · see citing works

Microglial activation‐mediated delayed and progressive degeneration of rat nigral dopaminergic neurons: relevance to Parkinson's disease

Gao, H., Jiang, J., Wilson, B. C., Zhang, W., Hong, J., & Liu, B. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00928.x · Cited by 690 · see citing works

Nonsteroidal Anti-inflammatory Drugs and the Risk of Parkinson Disease

Chen, H., Zhang, S. M., Hernán, M. Á., Schwarzschild, M. A., Willett, W. C., Colditz, G. A., Speizer, F. E., & Ascherio, A. (2003) · Archives of Neurology · doi:10.1001/archneur.60.8.1059 · Cited by 630 · see citing works

Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity.

Przedborski, S., Jackson-Lewis, V. R., Yokoyama, R., Shibata, T., Dawson, V. L., & Dawson, T. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.10.4565 · Cited by 624 · see citing works

Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease

Boka, G., Anglade, P., Wallach, D., Javoy-Agid, F., Agid, Y., & Hirsch, É. C. (1994) · Neuroscience Letters · doi:10.1016/0304-3940(94)90684-x · Cited by 591 · see citing works

Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease

Sulzer, D. (2007) · Trends in Neurosciences · doi:10.1016/j.tins.2007.03.009 · Cited by 583 · see citing works

Interleukin (IL)-1β, IL-2, IL-4, IL-6 and transforming growth factor-α levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease

Mogi, M., Harada, M., Narabayashi, H., Inagaki, H., Minami, M., & Nagatsu, T. (1996) · Neuroscience Letters · doi:10.1016/0304-3940(96)12706-3 · Cited by 545 · see citing works

Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease

Chen, H., Jacobs, E. J., Schwarzschild, M. A., McCullough, M. L., Calle, E. E., Thun, M. J., & Ascherio, A. (2005) · Annals of Neurology · doi:10.1002/ana.20682 · Cited by 470 · see citing works

Neuroinflammation of the nigrostriatal pathway during progressive 6‐OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging

Cicchetti, F., Brownell, A., Williams, K. S., Chen, Y. I., Livni, E., & Ole Isacson, A. (2002) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2002.01938.x · Cited by 406 · see citing works

Lipopolysaccharide Intranigral Injection Induces Inflammatory Reaction and Damage in Nigrostriatal Dopaminergic System

Castaño, A., Herrera, A. J., Cano, J., & Machado, A. (1998) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.1998.70041584.x · Cited by 393 · see citing works

The Single Intranigral Injection of LPS as a New Model for Studying the Selective Effects of Inflammatory Reactions on Dopaminergic System

Herrera, A. J., Castaño, A., Venero, J. L., Cano, J., & Machado, A. (2000) · Neurobiology of Disease · doi:10.1006/nbdi.2000.0289 · Cited by 392 · see citing works

FcεRII/CD23 Is Expressed in Parkinson’s Disease and Induces,In Vitro,Production of Nitric Oxide and Tumor Necrosis Factor-α in Glial Cells

Hunot, S., Dugas, N., Faucheux, B. A., Hartmann, A., Tardieu, M., Debré, P., Agid, Y., Dugas, B., & Hirsch, É. C. (1999) · Journal of Neuroscience · doi:10.1523/jneurosci.19-09-03440.1999 · Cited by 365 · see citing works

Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: Implications for Parkinson's disease

Sriram, K., Matheson, J. M., Benkovic, S. A., Miller, D. B., Luster, M. I., & O'Callaghan, J. P. (2002) · The FASEB Journal · doi:10.1096/fj.02-0216fje · Cited by 362 · see citing works

Blocking Soluble Tumor Necrosis Factor Signaling with Dominant-Negative Tumor Necrosis Factor Inhibitor Attenuates Loss of Dopaminergic Neurons in Models of Parkinson's Disease

McCoy, M. K., Martinez, T. N., Ruhn, K. A., Szymkowski, D. E., Smith, C. G., Botterman, B. R., Tansey, K. E., & Tansey, M. G. (2006) · Journal of Neuroscience · doi:10.1523/jneurosci.1504-06.2006 · Cited by 355 · see citing works

Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum

He, Y., Appel, S. H., & Le, W. (2001) · Brain Research · doi:10.1016/s0006-8993(01)02681-6 · Cited by 350 · see citing works

Peripheral Inflammatory Biomarkers and Risk of Parkinson's Disease

Chen, H., O'Reilly, E. J., Schwarzschild, M. A., & Ascherio, A. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwm260 · Cited by 317 · see citing works

Involvement of Interferon-γ in Microglial-Mediated Loss of Dopaminergic Neurons

Mount, M. P., Lira, A., Grimes, D., Smith, P. D., Faucher, S., Slack, R. S., Anisman, H., Hayley, S. P., & Park, D. S. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.5321-06.2007 · Cited by 316 · see citing works

Constitutive and Interleukin-1 (IL-1)-Inducible Factors Interact with the IL-1-Responsive Element in the IL-6 Gene

Isshiki, H., Akira, S., Tanabe, O., Nakajima, T., Shimamoto, T., Hirano, T., & Kishimoto, T. (1990) · Molecular and Cellular Biology · doi:10.1128/mcb.10.6.2757 · Cited by 285 · see citing works

The expression and function of chemokines involved in CNS inflammation

Ubogu, E. E., Cossoy, M. B., & Ransohoff, R. M. (2005) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2005.11.002 · Cited by 277 · see citing works

Role of ICAM-1 in persisting inflammation in Parkinson disease and MPTP monkeys

Judith Miklossy, A., Doudet, D., Schwab, C., Yu, S. Y., McGeer, E. G., & McGeer, P. L. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2005.10.034 · Cited by 255 · see citing works

1918 INFLUENZA, ENCEPHALITIS LETHARGICA, PARKINSONISM

Ravenholt, R. T., & Foege, W. (1982) · The Lancet · doi:10.1016/s0140-6736(82)90820-0 · Cited by 248 · see citing works

p53 protein, interferon-γ, and NF-κB levels are elevated in the parkinsonian brain

Mogi, M., Kondo, T., Mizuno, Y., & Nagatsu, T. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2006.12.003 · Cited by 242 · see citing works

The degenerative effect of a single intranigral injection of LPS on the dopaminergic system is prevented by dexamethasone, and not mimicked by rh‐TNF‐α, IL‐1β and IFN‐γ

Castaño, A., Herrera, A. J., Cano, J., & Machado, A. M. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.00799.x · Cited by 239 · see citing works

Exaggerated sickness behavior and brain proinflammatory cytokine expression in aged mice in response to intracerebroventricular lipopolysaccharide

Huang, Y., Henry, C. J., Dantzer, R., Johnson, R. W., & Godbout, J. P. (2007) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.04.012 · Cited by 218 · see citing works

Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease

Wahner, A. D., Bronstein, J. M., Bordelon, Y. M., & Ritz, B. R. (2007) · Neurology · doi:10.1212/01.wnl.0000279519.99344.ad · Cited by 210 · see citing works

Head trauma preceding PD

Bower, J. H., Maraganore, D. M., Peterson, B. J., McDonnell, S. K., Ahlskog, J. E., & Rocca, W. A. (2003) · Neurology · doi:10.1212/01.wnl.0000068008.78394.2c · Cited by 206 · see citing works

Selective COX-2 inhibition prevents progressive dopamine neuron degeneration in a rat model of Parkinson's disease.

Sánchez‐Pernaute, R., Ferree, A. W., Cooper, O., Yu, M., Brownell, A., & Ole Isacson, A. (2004) · Journal of Neuroinflammation · doi:10.1186/1742-2094-1-6 · Cited by 205 · see citing works

METHYLDOPA AND HqMOLYTIC ANqMIA

Weiner, W. J. (1966) · The Lancet · doi:10.1016/s0140-6736(66)92290-2 · Cited by 196 · see citing works

Cell Type-Specific Interleukin-1β Signaling in the CNS

Srinivasan, D., Yen, J.-H. J., Joseph, D. J., & Friedman, W. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.5712-03.2004 · Cited by 192 · see citing works

Genetic ablation of tumor necrosis factor‐alpha (TNF‐α) and pharmacological inhibition of TNF‐synthesis attenuates MPTP toxicity in mouse striatum

Ferger, B., Leng, A., Mura, A., Hengerer, B., & Feldon, J. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02399.x · Cited by 187 · see citing works

Tumor necrosis factor induces rapid production of 1'2'diacylglycerol by a phosphatidylcholine-specific phospholipase C.

Schütze, S., Berkovic, D., Tomsing, O., Unger, C., & Krönke, M. (1991) · The Journal of Experimental Medicine · doi:10.1084/jem.174.5.975 · Cited by 183 · see citing works

Blood-borne interleukin-1 receptor antagonist crosses the blood-brain barrier

GUTIERREZ, E., Banks, W. A., & Kastin, A. J. (1994) · Journal of Neuroimmunology · doi:10.1016/0165-5728(94)90005-1 · Cited by 176 · see citing works

Risk factors for dopaminergic neuron loss in human α‐synuclein transgenic mice

Thiruchelvam, M. J., Powers, J. M., Cory‐Slechta, D. A., & Richfield, E. K. (2004) · European Journal of Neuroscience · doi:10.1111/j.0953-816x.2004.03139.x · Cited by 174 · see citing works

Systemic Infusion of Naloxone Reduces Degeneration of Rat Substantia Nigral Dopaminergic Neurons Induced by Intranigral Injection of Lipopolysaccharide

Liu, B., Jiang, J., Wilson, B. C., Du, L., Yang, S., Wang, J., Wu, G.-C., Cao, X.-D., & Hong, J. (2000) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)38877-9 · Cited by 167 · see citing works

Progressive Dopamine Neuron Loss in Parkinson's Disease: The Multiple Hit Hypothesis

Carvey, P. M., Punati, A., & Newman, M. B. (2006) · Cell Transplantation · doi:10.3727/000000006783981990 · Cited by 164 · see citing works

The advent of the cytokine storm

Clark, I. A. (2007) · Immunology and Cell Biology · doi:10.1038/sj.icb.7100062 · Cited by 160 · see citing works

Progressive dopamine neuron loss following supra-nigral lipopolysaccharide (LPS) infusion into rats exposed to LPS prenatally

Ling, Z., Zhu, Y., Tong, C. W., Snyder, J. A., Lipton, J. W., & Carvey, P. M. (2006) · Experimental Neurology · doi:10.1016/j.expneurol.2006.01.010 · Cited by 160 · see citing works

Iron and Paraquat as Synergistic Environmental Risk Factors in Sporadic Parkinson's Disease Accelerate Age-Related Neurodegeneration

Peng, J., Peng, L., Stevenson, F. F., Doctrow, S. R., & Andersen, J. K. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.1569-07.2007 · Cited by 150 · see citing works

Nonsteroidal anti‐inflammatory drugs and risk of Parkinson's disease

Ton, T. G. N., Heckbert, S. R., Longstreth, W. T., Jr., Rossing, M. A., Kukull, W. A., Franklin, G. M., Swanson, P. D., Smith‐Weller, T., & Checkoway, H. (2006) · Movement Disorders · doi:10.1002/mds.20856 · Cited by 141 · see citing works

The IL-1 receptor signaling pathway

Kuno, K., & Matsushima, K. (1994) · Journal of Leukocyte Biology · doi:10.1002/jlb.56.5.542 · Cited by 132 · see citing works

Interleukin-1 Receptor Antagonist Penetrates Human Brain at Experimentally Therapeutic Concentrations

Clark, S., McMahon, C. J., Gueorguieva, I., Rowland, M., Scarth, S., Georgiou, R. F., Tyrrell, P. J., Hopkins, S. J., & Rothwell, N. J. (2007) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600537 · Cited by 123 · see citing works

Association of interleukin-1β polymorphisms with idiopathic Parkinson's disease

McGeer, P. L., Yasojima, K., & McGeer, E. G. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(02)00300-2 · Cited by 118 · see citing works

Dexamethasone protects against dopaminergic neurons damage in a mouse model of Parkinson's disease

Kurkowska-Jastrzębska, I., Litwin, T., Joniec, I., Ciesielska, A., Przybyłkowski, A., Członkowski, A., & Członkowska, A. (2004) · International Immunopharmacology · doi:10.1016/j.intimp.2004.05.006 · Cited by 117 · see citing works

Combined toxicity of prenatal bacterial endotoxin exposure and postnatal 6-hydroxydopamine in the adult rat midbrain

Ling, Z. D., Chang, Q., Lipton, J. W., Tong, C. W., Landers, T. M., & Carvey, P. M. (2004) · Neuroscience · doi:10.1016/j.neuroscience.2003.12.017 · Cited by 114 · see citing works

Tumor Necrosis Factor Signal Transduction

Schütze, S., Scheurich, P., Pfizenmaier, K., & Krönke, M. (1989) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)94102-5 · Cited by 113 · see citing works

Mitochondrial Impairment Reduces the Threshold for in Vivo NMDA-Mediated Neuronal Death in the Striatum

Simpson, J. R., & Isacson, O. (1993) · Experimental Neurology · doi:10.1006/exnr.1993.1071 · Cited by 113 · see citing works

Immunologic diseases, anti-inflammatory drugs, and Parkinson disease: A case-control study

Bower, J. H., Maraganore, D. M., Peterson, B. J., Ahlskog, J. E., & Rocca, W. A. (2006) · Neurology · doi:10.1212/01.wnl.0000227906.99570.cc · Cited by 113 · see citing works

Smoking, Caffeine, and Nonsteroidal Anti-inflammatory Drugs in Families With Parkinson Disease

Hancock, D. B., Martin, E. R., Stajich, J. M., Jewett, R. M., Stacy, M. A., Scott, B. L., Vance, J. M., & Scott, W. K. (2007) · Archives of Neurology · doi:10.1001/archneur.64.4.576 · Cited by 109 · see citing works

Influence of interleukin-1β gene polymorphisms on age-at-onset of sporadic Parkinson's disease

Nishimura, M., Mizuta, I., Mizuta, E., Yamasaki, S., Ohta, M., & Kuno, S. (2000) · Neuroscience Letters · doi:10.1016/s0304-3940(00)00991-5 · Cited by 104 · see citing works

Polymorphisms in the interleukin-1 alpha and beta genes and the risk for Parkinson's disease

Schulte, T., Schöls, L. J., Müller, T. H., Woitalla, D., Berger, K., & Krüger, R. (2002) · Neuroscience Letters · doi:10.1016/s0304-3940(02)00301-4 · Cited by 104 · see citing works

Intra-parenchymal injection of tumor necrosis factor-? and interleukin 1-? produces dopamine neuron loss in the rat

Carvey, P. M., Chen, E.-Y., Lipton, J. W., Tong, C. W., Chang, Q. A., & Ling, Z. D. (2004) · Journal of Neural Transmission · doi:10.1007/s00702-004-0222-z · Cited by 83 · see citing works

Prior history of head trauma in Parkinson's disease

Factor, S. A., & Weiner, W. J. (1991) · Movement Disorders · doi:10.1002/mds.870060306 · Cited by 78 · see citing works

Chemokines in the MPTP model of Parkinson’s disease: Absence of CCL2 and its receptor CCR2 does not protect against striatal neurodegeneration

Kalkonde, Y. V., MORGAN, W. W., Sigala, J. A., Maffi, S. K., Condello, C., Kuziel, W. A., Ahuja, S. S., & Ahuja, S. K. (2006) · Brain Research · doi:10.1016/j.brainres.2006.08.041 · Cited by 75 · see citing works

Activation of peroxisome proliferator-activated receptor-γ protects pancreatic β-cells from cytokine-induced cytotoxicity via NFκB pathway

Kim, E., Kwon, K., Koo, B.-S., Han, M.-J., Song, M., Song, E.-K., Han, M., Park, J., Ryu, D., & Park, B. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.04.005 · Cited by 75 · see citing works

On neuronal health

Ole Isacson, A. (1993) · Trends in Neurosciences · doi:10.1016/0166-2236(93)90104-t · Cited by 72 · see citing works

Interleukin‐1β but not tumor necrosis factor‐α potentiates neuronal damage by quinolinic acid: Protection by an adenosine A2Areceptor antagonist

Stone, T. W., & Behan, W. M. H. (2007) · Journal of Neuroscience Research · doi:10.1002/jnr.21212 · Cited by 67 · see citing works

Dopamine‐dependent neurotoxicity of lipopolysaccharide in substantia nigra

de Pablos, R. M., Herrera, A. J., Villarán, R. F., Cano, J., & Machado, A. (2004) · The FASEB Journal · doi:10.1096/fj.04-2153fje · Cited by 45 · see citing works

Differential and Cooperative Effects of TNFα, IL-1β, and IFNγ on Human Conjunctival Epithelial Cell Receptor Expression and Chemokine Release

Stahl, J. L., Cook, E. B., Graziano, F. M., & Barney, N. P. (2003) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.02-0721 · Cited by 45 · see citing works

Tumor necrosis factor-alpha receptor ablation in a chronic MPTP mouse model of Parkinson's disease

Leng, A., Mura, A., Feldon, J., & Ferger, B. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.10.077 · Cited by 43 · see citing works

Lack of detection of influenza genes in archived formalin-fixed, paraffin wax-embedded brain samples of encephalitis lethargica patients from 1916 to 1920.

Lo, K. C., Geddes, J. F., Daniels, R. S., & OXFORD, J. S. (2003) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-003-0795-1 · Cited by 41 · see citing works

A possible role of influenza A virus infection for Parkinson's disease.

Takahashi, M., & Yamada, T. (2001) · PubMed · Cited by 40 · see citing works

Prolonged exposure to IL-1β and IFNγ induces necrosis of L929 tumor cells via a p38MAPK/NF-κB/NO-dependent mechanism

Vercammen, E., Staal, J., Broeke, A. V. D., Haegman, M., Vereecke, L., Schotte, P., & Beyaert, R. (2008) · Oncogene · doi:10.1038/onc.2008.4 · Cited by 23 · see citing works

Cryptococcal meningoencephalitis with parkinsonian features

Wszołek, Z. K., Monsour, H., Smith, P. W., & Pfeiffer, R. F. (1988) · Movement Disorders · doi:10.1002/mds.870030312 · Cited by 19 · see citing works

Dopamine imaging markers and predictive mathematical models for progressive degeneration in Parkinson's disease

Brownell, A., Jenkins, B. G., & Ole Isacson, A. (1999) · Biomedicine & Pharmacotherapy · doi:10.1016/s0753-3322(99)80078-x · Cited by 19 · see citing works

Gene treatment of cerebral stroke by rAAV vector delivering IL-1ra in a rat model

Tsai, T.-H., Chen, S., Xiao, X., Chiang, Y. H., Lin, S., Kuo, S.-W., Liu, D.-W., & Tsao, Y. (2003) · Neuroreport · doi:10.1097/00001756-200305060-00005 · Cited by 17 · see citing works

Postencephalitic Parkinson's disease, amyotrophic lateral sclerosis on Guam and influenza revisited: focusing on neurofibrillary tangles and the trail of tau

MAURIZI, C. P. (2002) · Medical Hypotheses · doi:10.1054/mehy.2000.1224 · Cited by 9 · see citing works

Exaggerated sickness behavior and brain proinflammatory cytokine expression in aged mice in response to intracerebroventricular lipopolysaccharide

Henry, C. J., Huang, Y., Dantzer, R., Johnson, R. W., & Godbout, J. P. (2007) · The Journal of Immunology · Cited by 7 · see citing works

A neuropathologic study of long‐term, Economo‐type postencephalitic parkinsonism with a prolonged clinical course

Mizukami, K., Sasaki, M., Shiraishi, H., Ikeda, K., & Kosaka, K. (1996) · Psychiatry and Clinical Neurosciences · doi:10.1111/j.1440-1819.1996.tb01667.x · Cited by 2 · see citing works

Neuroinflammation in Parkinson’s disease: A target for neuroprotection?

Hirsch, E. C., & Hunot, S. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70062-6 · Cited by 1,984 · see citing works

Role of neuroinflammation in neurodegeneration development

Zhang, W., Xiao, D., Mao, Q., & Xia, H. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01486-5 · Cited by 1,668 · see citing works

The central nervous system and the gut microbiome

Sharon, G., Sampson, T. R., Geschwind, D. H., & Mazmanian, S. K. (2016) · Cell · doi:10.1016/j.cell.2016.10.027 · Cited by 1,513 · see citing works

Inflammation in neurodegenerative diseases

Amor, S., Puentes, F., Baker, D., & Van Der Valk, P. (2010) · Immunology · doi:10.1111/j.1365-2567.2009.03225.x · Cited by 1,355 · see citing works

Inflammasome inhibition prevents α-synuclein pathology and dopaminergic neurodegeneration in mice

Gordon, R., Albornoz, E. A., Christie, D. C., Langley, M. R., Kumar, V., Mantovani, S., Robertson, A. A. B., Butler, M. S., Rowe, D. B., O’Neill, L. A., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aah4066 · Cited by 897 · see citing works

The Role of Astrocyte Dysfunction in Parkinson’s Disease Pathogenesis

Booth, H. D. E., Hirst, W. D., & Wade-Martins, R. (2017) · Trends in Neurosciences · doi:10.1016/j.tins.2017.04.001 · Cited by 633 · see citing works

Peripheral cytokines profile in parkinson’s disease

Reale, M., Iarlori, C., Thomas, A., Gambi, D., Perfetti, B., Di Nicola, M., & Onofrj, M. (2009) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2008.07.003 · Cited by 547 · see citing works

Ferroptosis and its potential role in the physiopathology of Parkinson’s Disease

Mahoney‐Sanchez, L., Bouchaoui, H., Ayton, S., Devos, D., Duce, J. A., & Devedjian, J.-C. (2020) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2020.101890 · Cited by 558 · see citing works

Highly pathogenic H5N1 influenza virus can enter the central nervous system and induce neuroinflammation and neurodegeneration

Jang, H., Boltz, D., Sturm-Ramirez, K., Shepherd, K., Jiao, Y., Webster, R., & Smeyne, R. J. (2009) · Proceedings of the National Academy of Sciences of the United States of America · doi:10.1073/pnas.0900096106 · Cited by 464 · see citing works

MicroRNA-7 targets Nod-like receptor protein 3 inflammasome to modulate neuroinflammation in the pathogenesis of Parkinson’s disease

Zhou, Y., Lu, M., Du, R.-H., Qiao, C., Jiang, C.-Y., Zhang, K.-Z., Ding, J.-H., & Hu, G. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0094-3 · Cited by 455 · see citing works

The mechanisms of NLRP3 inflammasome/pyroptosis activation and their role in Parkinson's disease

Wang, S., Yuan, Y., Chen, N., & Wang, H. (2018) · International Immunopharmacology · doi:10.1016/j.intimp.2018.12.019 · Cited by 447 · see citing works

MPTP-driven NLRP3 inflammasome activation in microglia plays a central role in dopaminergic neurodegeneration

Lee, E., Hwang, I., Park, S., Hong, S., Hwang, B., Cho, Y., Son, J., & Yu, J.-W. (2019) · Cell Death &amp; Differentiation · doi:10.1038/s41418-018-0124-5 · Cited by 431 · see citing works

Dynamic Changes in Presynaptic and Axonal Transport Proteins Combined with Striatal Neuroinflammation Precede Dopaminergic Neuronal Loss in a Rat Model of AAV α-Synucleinopathy

Chung, C. Y., Koprich, J. B., Siddiqi, H. K., & Ole Isacson, A. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.5427-08.2009 · Cited by 392 · see citing works

Neuroprotective effect of resveratrol on 6-OHDA-induced Parkinson's disease in rats

Jin, F. J., Wu, Q., Lu, Y., Gong, Q., & Shi, J. (2008) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2008.10.005 · Cited by 384 · see citing works

NLRP3 inflammasome is expressed and functional in mouse brain microglia but not in astrocytes

Gustin, A., Kirchmeyer, M., Koncina, E., Felten, P., Losciuto, S., Heurtaux, T., Tardivel, A., Heuschling, P., & Dostert, C. (2015) · PLoS ONE · doi:10.1371/journal.pone.0130624 · Cited by 369 · see citing works

Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson’s disease

Pott Godoy, M. C., Tarelli, R., Ferrari, C. C., Sarchi, M. I., & Pitossi, F. J. (2008) · Brain · doi:10.1093/brain/awn101 · Cited by 335 · see citing works

Ferroptosis and cell death mechanisms in Parkinson's disease

Guiney, S. J., Adlard, P. A., Bush, A. I., Finkelstein, D. I., & Ayton, S. (2017) · Neurochemistry International · doi:10.1016/j.neuint.2017.01.004 · Cited by 337 · see citing works

Contributions of central and systemic inflammation to the pathophysiology of Parkinson's disease

Collins, L. M., Toulouse, A., Connor, T. J., & Nolan, Y. M. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.01.028 · Cited by 275 · see citing works

The influence of microglia on the pathogenesis of Parkinson's disease

Long-Smith, C. M., Sullivan, A. M., & Nolan, Y. M. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2009.08.001 · Cited by 296 · see citing works

Anti-inflammatory effects of BHBA in both in vivo and in vitro Parkinson’s disease models are mediated by GPR109A-dependent mechanisms

Fu, S., Wang, J., Xue, W.-J., Liu, H., Liu, B.-R., Zeng, Y., Li, S., Huang, B., Lv, Q.-K., Wang, W., et al. (2015) · Journal of Neuroinflammation · doi:10.1186/s12974-014-0230-3 · Cited by 269 · see citing works

Parkin Deficiency Increases Vulnerability to Inflammation-Related Nigral Degeneration

Frank-Cannon, T. C., Tran, T. A. T., Ruhn, K. A., Martinez, T. N., Hong, J. J., Marvin, M. A., Hartley, M., Treviño, I., O’Brien, D. E., Casey, B. H., et al. (2008) · Journal of Neuroscience · doi:10.1523/jneurosci.3001-08.2008 · Cited by 262 · see citing works

Prussian Blue Nanozyme as a Pyroptosis Inhibitor Alleviates Neurodegeneration

Ma, X., Hao, J., Wu, J., Li, Y., Cai, X., & Zheng, Y. (2022) · Advanced Materials · doi:10.1002/adma.202106723 · Cited by 253 · see citing works

Neurodegenerative Diseases – Is Metabolic Deficiency the Root Cause?

Muddapu, V. R., Dharshini, S. A. P., Chakravarthy, V. S., & Gromiha, M. M. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00213 · Cited by 248 · see citing works

The role of the LRRK2 gene in Parkinsonism

Li, J.-Q., Tan, L., & Yu, J.-T. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-47 · Cited by 249 · see citing works

IL-1 Family Members Mediate Cell Death, Inflammation and Angiogenesis in Retinal Degenerative Diseases

Wooff, Y., Man, S. M., Aggio‐Bruce, R., Natoli, R., & Fernando, N. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01618 · Cited by 244 · see citing works

Neuroimmunological Processes in Parkinson’s Disease and their Relation to α-Synuclein: Microglia as the Referee between Neuronal Processes and Peripheral Immunity

Sánchez-Guajardo, V., Barnum, C. J., Tansey, M. G., & Romero‐Ramos, M. (2013) · ASN NEURO · doi:10.1042/an20120066 · Cited by 237 · see citing works

The Role of Sex and Sex Hormones in Neurodegenerative Diseases

Vegeto, E., Villa, A. M., Torre, S. D., Crippa, V., Rusmini, P., Cristofani, R., Galbiati, M., Maggi, A. C., & Poletti, A. (2019) · Endocrine Reviews · doi:10.1210/endrev/bnz005 · Cited by 231 · see citing works

Parkinson's Disease and Systemic Inflammation

Ferrari, C. C., & Tarelli, R. (2011) · Parkinson s Disease · doi:10.4061/2011/436813 · Cited by 218 · see citing works

Mitochondria and the NLRP3 inflammasome: physiological and pathological relevance

Yu, J., & Lee, M. (2016) · Archives of Pharmacal Research · doi:10.1007/s12272-016-0827-4 · Cited by 207 · see citing works

Chemokine CCL2–CCR2 Signaling Induces Neuronal Cell Death via STAT3 Activation and IL-1β Production after Status Epilepticus

Tian, D., Peng, J., Murugan, M., Feng, L.-J., Liu, J., Eyo, U. B., Zhou, L., Mogilevsky, R., Wang, W., & Wu, L. (2017) · Journal of Neuroscience · doi:10.1523/jneurosci.0315-17.2017 · Cited by 201 · see citing works

Lewy body-like alpha-synuclein inclusions trigger reactive microgliosis prior to nigral degeneration

Duffy, M. F., Collier, T. J., Patterson, J. R., Kemp, C. J., Luk, K. C., Tansey, M. G., Paumier, K. L., Kanaan, N. M., Fischer, D. L., Polinski, N. K., et al. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1171-z · Cited by 197 · see citing works

Baicalein exerts neuroprotective effects in 6-hydroxydopamine-induced experimental parkinsonism in vivo and in vitro

Mu, X. L., He, G., Cheng, Y., Li, X., Xu, B., & Du, G. (2009) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2009.03.008 · Cited by 194 · see citing works

The Threshold Theory for Parkinson's Disease

Engelender, S., & Ole Isacson, A. (2016) · Trends in Neurosciences · doi:10.1016/j.tins.2016.10.008 · Cited by 194 · see citing works

Neuroinflammation and Parkinson’s Disease—From Neurodegeneration to Therapeutic Opportunities

Araújo, B., Caridade-Silva, R., Soares-Guedes, C., Martins‐Macedo, J., Gomes, E. D., Monteiro, S., & Teixeira, F. G. (2022) · Cells · doi:10.3390/cells11182908 · Cited by 198 · see citing works

Rutin Protects Dopaminergic Neurons from Oxidative Stress in an Animal Model of Parkinson’s Disease

Khan, M. M., Raza, S. S., Javed, H., Ahmad, A., Khan, A., Islam, F., Safhi, M. M., & Islam, F. (2011) · Neurotoxicity Research · doi:10.1007/s12640-011-9295-2 · Cited by 186 · see citing works

Central pathways causing fatigue in neuro-inflammatory and autoimmune illnesses

Morris, G., Berk, M., Walder, K. R., & Maes, M. H. J. (2015) · BMC Medicine · doi:10.1186/s12916-014-0259-2 · Cited by 179 · see citing works

Metabolic alterations in Parkinson’s disease astrocytes

Sonninen, T.-M., Hämäläinen, R. H., Koskuvi, M., Oksanen, M., Shakirzyanova, A., Wojciechowski, S., Puttonen, K. A., Naumenko, N. V., Goldsteins, G., Laham-Karam, N., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-71329-8 · Cited by 181 · see citing works

Pharmacological blockade of IL-1β/IL-1 receptor type 1 axis during epileptogenesis provides neuroprotection in two rat models of temporal lobe epilepsy

Noè, F. M., Polascheck, N., Frigerio, F., Bankstahl, M., Ravizza, T., Marchini, S., Beltrame, L., Reschke, C. R., Löscher, W., & Vezzani, A. (2013) · Neurobiology of Disease · doi:10.1016/j.nbd.2013.07.015 · Cited by 177 · see citing works

Interleukin-1β and tumor necrosis factor-α: reliable targets for protective therapies in Parkinson’s Disease?

Leal, M. C., Casabona, J. C., Puntel, M., & Pitossi, F. J. (2013) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2013.00053 · Cited by 175 · see citing works

Neuroinflammation in Parkinson’s Disease

Lee, J., Tran, T. A. T., & Tansey, M. G. (2009) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-009-9176-0 · Cited by 174 · see citing works

IL-1 family cytokines trigger sterile inflammatory disease

Lukens, J. R., Gross, J. M., & Kanneganti, T. (2012) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00315 · Cited by 172 · see citing works

Significant roles of neuroinflammation in Parkinson’s disease: therapeutic targets for PD prevention

Lee, Y., Lee, S., Chang, S., & Lee, J. (2019) · Archives of Pharmacal Research · doi:10.1007/s12272-019-01133-0 · Cited by 169 · see citing works

The role of inflammation in sporadic and familial Parkinson’s disease

Deleidi, M., & Gasser, T. (2013) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-013-1352-y · Cited by 167 · see citing works

Long Noncoding RNA SNHG1 Promotes Neuroinflammation in Parkinson’s Disease via Regulating miR-7/NLRP3 Pathway

Cao, B., Wang, T., Qu, Q., Kang, T., & Yang, Q. (2018) · Neuroscience · doi:10.1016/j.neuroscience.2018.07.019 · Cited by 167 · see citing works

Axon guidance and synaptic maintenance: preclinical markers for neurodegenerative disease and therapeutics

Lin, L., Lesnick, T. G., Maraganore, D. M., & Ole Isacson, A. (2009) · Trends in Neurosciences · doi:10.1016/j.tins.2008.11.006 · Cited by 165 · see citing works

Neuroprotective effects of resveratrol in an MPTP mouse model of Parkinson's-like disease: Possible role of SOCS-1 in reducing pro-inflammatory responses

Lofrumento, D. D., Nicolardi, G., Cianciulli, A., Nuccio, F. D., Pesa, V. L., Carofiglio, V. E., Dragone, T., Calvello, R., & Panaro, M. A. (2013) · Innate Immunity · doi:10.1177/1753425913488429 · Cited by 156 · see citing works

MicroRNA-124 regulates the expression of MEKK3 in the inflammatory pathogenesis of Parkinson’s disease

Yao, L., Ye, Y., Mao, H., Lu, F., He, X., Lu, G., & Zhang, S. (2018) · Journal of Neuroinflammation · doi:10.1186/s12974-018-1053-4 · Cited by 159 · see citing works

The NLRP3 Inflammasome is Involved in the Pathogenesis of Parkinson’s Disease in Rats

Mao, Z., Liu, C., Ji, S., Yang, Q., Ye, H., Han, H., & Xue, Z. (2017) · Neurochemical Research · doi:10.1007/s11064-017-2185-0 · Cited by 155 · see citing works

Neuroinflammation, gut microbiome, and Alzheimer's disease

Lin, L., Zheng, L. J., & Zhang, L. J. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-0983-2 · Cited by 147 · see citing works

IL-1β induces rod degeneration through the disruption of retinal glutamate homeostasis

Charles‐Messance, H., Blot, G., Couturier, A., Vignaud, L., Touhami, S., Béguier, F., Siqueiros‐Márquez, L., Forster, V., Barmo, N., Augustin, S., et al. (2020) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1655-5 · Cited by 154 · see citing works

Time-course of nigrostriatal neurodegeneration and neuroinflammation in the 6-hydroxydopamine-induced axonal and terminal lesion models of Parkinson's disease in the rat

Walsh, S. R., Finn, D. P., & Dowd, E. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.12.005 · Cited by 152 · see citing works

Role of inflammatory cytokines in depression: Focus on interleukin-1β

Farooq, R. K., Asghar, K., Kanwal, S., & Zulqernain, A. (2016) · Biomedical Reports · doi:10.3892/br.2016.807 · Cited by 151 · see citing works

The increase of carcinoembryonic antigen (CEA), high-sensitivity C-reactive protein, and neutrophil/lymphocyte ratio in Parkinson’s disease

Akıl, E., Bulut, A., Kaplan, İ., Özdemir, H. H., Arslan, D., & Aluçlu, M. U. (2014) · Neurological Sciences · doi:10.1007/s10072-014-1976-1 · Cited by 148 · see citing works

Glial Cells as Players in Parkinsonism: The “Good,” the “Bad,” and the “Mysterious” Glia

Mena, M. A., & de Yébenes, J. G. (2008) · The Neuroscientist · doi:10.1177/1073858408322839 · Cited by 141 · see citing works

Tenuigenin protects dopaminergic neurons from inflammation via suppressing NLRP3 inflammasome activation in microglia

Fan, Z., Liang, Z., Yang, H. M., Pan, Y., Zheng, Y., & Wang, X. (2017) · Journal of Neuroinflammation · doi:10.1186/s12974-017-1036-x · Cited by 134 · see citing works

Interleukin 1 receptor antagonist and soluble tumor necrosis factor receptor 1 are associated with general severity and psychotic symptoms in schizophrenia and bipolar disorder

Hope, S., Ueland, T., Steen, N. E., Dieset, I., Lorentzen, S., Berg, A. O., Agartz, I., Aukrust, P., & Andreassen, O. A. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2012.12.023 · Cited by 131 · see citing works

IL-1 family cytokines in inflammation and immunity

Garlanda, C., Ceglie, I. D., & Jaillon, S. (2025) · Cellular and Molecular Immunology · doi:10.1038/s41423-025-01358-8 · Cited by 143 · see citing works

The glycoprotein GPNMB is selectively elevated in the substantia nigra of Parkinson's disease patients and increases after lysosomal stress

Moloney, E. B., Moskites, A., Ferrari, E. J., Ole Isacson, A., & Hallett, P. J. (2018) · Neurobiology of Disease · doi:10.1016/j.nbd.2018.08.013 · Cited by 128 · see citing works

Periventricular white matter damage in the hypoxic neonatal brain: Role of microglial cells

Kaur, C., & Ling, E. A. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2009.01.003 · Cited by 118 · see citing works

Activation of microglia induces symptoms of Parkinson’s disease in wild-type, but not in IL-1 knockout mice

Tanaka, S., Ishii, A., Ohtaki, H., Shioda, S., Yoshida, T., & Numazawa, S. (2013) · Journal of Neuroinflammation · doi:10.1186/1742-2094-10-143 · Cited by 118 · see citing works

Characterization of the lipopolysaccharide induced model of Parkinson's disease: Role of oxidative stress and neuroinflammation

Sharma, N., & Nehru, B. (2015) · Neurochemistry International · doi:10.1016/j.neuint.2015.06.004 · Cited by 115 · see citing works

Neurodegeneration by α-synuclein-specific T cells in AAV-A53T-α-synuclein Parkinson’s disease mice

Karikari, A. A., McFleder, R. L., Ribechini, E., Blum, R., Bruttel, V., Knorr, S., Gehmeyr, M., Volkmann, J., Brotchie, J. M., Ahsan, F., et al. (2022) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2022.01.007 · Cited by 116 · see citing works

Delayed Dominant-Negative TNF Gene Therapy Halts Progressive Loss of Nigral Dopaminergic Neurons in a Rat Model of Parkinson's Disease

Harms, A. S., Barnum, C. J., Ruhn, K. A., Varghese, S., Treviño, I., Blesch, A., & Tansey, M. G. (2010) · Molecular Therapy · doi:10.1038/mt.2010.217 · Cited by 117 · see citing works

Further characterisation of the LPS model of Parkinson’s disease: A comparison of intra-nigral and intra-striatal lipopolysaccharide administration on motor function, microgliosis and nigrostriatal neurodegeneration in the rat

Hoban, D. B., Connaughton, E., Connaughton, C., Hogan, G., Thornton, C., Mulcahy, P. J., Moloney, T. C., & Dowd, E. (2012) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2012.10.001 · Cited by 113 · see citing works

Inhibiting NLRP3 inflammasome activation prevents copper-induced neuropathology in a murine model of Wilson’s disease

Dong, J., Wang, X., Xu, C., Gao, M., Wang, S., Zhang, J. C., Tong, H., Wang, L., Han, Y., Cheng, N., et al. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03397-1 · Cited by 113 · see citing works

Brain renin-angiotensin system and dopaminergic cell vulnerability

Labandeira-García, J. L., Garrido‐Gil, P., Rodríguez‐Pallares, J., Valenzuela, R., Borrajo, A., & Rodriguez-Perez, A. I. (2014) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2014.00067 · Cited by 113 · see citing works

Anti-Inflammatory Modulation of Microglia via CD163-Targeted Glucocorticoids Protects Dopaminergic Neurons in the 6-OHDA Parkinson's Disease Model

Tentillier, N., Etzerodt, A., Olesen, M. N., Rizalar, F. S., Jacobsen, J., Bender, D., Moestrup, S. K., & Romero-Ramos, M. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.1636-16.2016 · Cited by 109 · see citing works

The Interplay between Alpha-Synuclein Clearance and Spreading

da Fonseca, T. L., Villar‐Piqué, A., & Outeiro, T. F. (2015) · Biomolecules · doi:10.3390/biom5020435 · Cited by 110 · see citing works

Immunotherapies for Neurodegenerative Diseases

Mortada, I., Farah, R., Nabha, S. M., Ojcius, D. M., Fares, Y., Almawi, W. Y., & Sadier, N. S. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.654739 · Cited by 112 · see citing works

Plasma profile of pro‐inflammatory cytokines and chemokines in cocaine users under outpatient treatment: influence of cocaine symptom severity and psychiatric co‐morbidity

Araos, P. F., Pedraz, M., Serrano, A., Lucena, M. A., Barrios, V., García‐Marchena, N., Campos‐Cloute, R., Ruiz, J. J., Romero‐Sanchiz, P., Suárez, J., et al. (2014) · Addiction Biology · doi:10.1111/adb.12156 · Cited by 107 · see citing works

The Endotoxin-Induced Neuroinflammation Model of Parkinson's Disease

Tüfekçi, K. U., Genç, Ş., & Genç, K. (2011) · Parkinson s Disease · doi:10.4061/2011/487450 · Cited by 108 · see citing works

Lipid and immune abnormalities causing age-dependent neurodegeneration and Parkinson’s disease

Hallett, P. J., Engelender, S., & Ole Isacson, A. (2019) · Journal of Neuroinflammation · doi:10.1186/s12974-019-1532-2 · Cited by 105 · see citing works

The Toll-Like Receptor-3 Agonist Polyinosinic:Polycytidylic Acid Triggers Nigrostriatal Dopaminergic Degeneration

Deleidi, M., Hallett, P. J., Koprich, J. B., Chung, C. Y., & Ole Isacson, A. (2010) · Journal of Neuroscience · doi:10.1523/jneurosci.2400-10.2010 · Cited by 101 · see citing works

Role of microglial redox balance in modulation of neuroinflammation

Innamorato, N. G., Lastres‐Becker, I., & Cuadrado, A. (2009) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32832a3225 · Cited by 100 · see citing works

Viral and Inflammatory Triggers of Neurodegenerative Diseases

Deleidi, M., & Ole Isacson, A. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003492 · Cited by 101 · see citing works

Emerging roles of microglial activation and non-motor symptoms in Parkinson's disease

Doorn, K. J., Lucassen, P. J., Boddeke, H. W. G. M., Prins, M., Berendse, H. W., Drukarch, B., & van Dam, A. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.06.005 · Cited by 97 · see citing works

Aging-related changes in the nigral angiotensin system enhances proinflammatory and pro-oxidative markers and 6-OHDA-induced dopaminergic degeneration

Villar‐Cheda, B., Valenzuela, R., Rodriguez-Perez, A. I., Guerra, M. J., & Labandeira-García, J. L. (2010) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.08.006 · Cited by 98 · see citing works

Neuroprotective effects of swimming training in a mouse model of Parkinson’s disease induced by 6-hydroxydopamine

Goes, A. T. R., Souza, L. C., Filho, C. B., Fabbro, L. D., de Gomes, M. G., Boeira, S. P., & Jessé, C. R. (2013) · Neuroscience · doi:10.1016/j.neuroscience.2013.09.042 · Cited by 98 · see citing works

Interferon-γ plays a role in paraquat-induced neurodegeneration involving oxidative and proinflammatory pathways

Mangano, E. N., Litteljohn, D., So, R., Nelson, E., Peters, S., Bethune, C., Bobyn, J., & Hayley, S. P. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.02.016 · Cited by 96 · see citing works

Imidazoline 2 binding sites reflecting astroglia pathology in Parkinson’s disease: an in vivo11C-BU99008 PET study

Wilson, H., Dervenoulas, G., Pagano, G., Tyacke, R. J., Polychronis, S., Myers, J., Gunn, R. N., Rabiner, E. A., Nutt, D., & Politis, M. (2019) · Brain · doi:10.1093/brain/awz260 · Cited by 93 · see citing works

Oral pelargonidin exerts dose-dependent neuroprotection in 6-hydroxydopamine rat model of hemi-parkinsonism

Roghani, M., Akram, N., Nadoushan, M. J., Kiasalari, Z., Khalili, M., & Baluchnejadmojarad, T. (2010) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2010.06.004 · Cited by 93 · see citing works

Inflammatory Mechanisms of Neurodegeneration in Toxin-Based Models of Parkinson's Disease

Litteljohn, D., Mangano, E. N., Clarke, M., Bobyn, J., Moloney, K., & Hayley, S. P. (2010) · Parkinson s Disease · doi:10.4061/2011/713517 · Cited by 94 · see citing works

Physical Training Regulates Mitochondrial Parameters and Neuroinflammatory Mechanisms in an Experimental Model of Parkinson’s Disease

Tuon, T., Souza, P. S., Santos, M. F., Pereira, F. T., Pedroso, G. S., Luciano, T. F., De Souza, C. T., Dutra, R. C., Silveira, P. C. L., & Pinho, R. A. (2015) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2015/261809 · Cited by 92 · see citing works

Modeling neuroinflammatory pathogenesis of Parkinson’s disease

Barnum, C. J., & Tansey, M. G. (2010) · Progress in brain research · doi:10.1016/s0079-6123(10)84006-3 · Cited by 91 · see citing works

Regulator of G-Protein Signaling-10 Negatively Regulates NF-κB in Microglia and Neuroprotects Dopaminergic Neurons in Hemiparkinsonian Rats

Lee, J., Chung, J., McAlpine, F. E., & Tansey, M. G. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.1002-11.2011 · Cited by 88 · see citing works

Reducing neuroinflammation via therapeutic compounds and lifestyle to prevent or delay progression of Parkinson’s disease

Kip, E., & Parr‐Brownlie, L. C. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101618 · Cited by 88 · see citing works

Activation of p38 MAPK in the substantia nigra leads to nuclear translocation of NF‐κB in MPTP‐treated mice: implication in Parkinson’s disease

Karunakaran, S., & Ravindranath, V. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06112.x · Cited by 87 · see citing works

Long noncoding RNA GAS5 promotes microglial inflammatory response in Parkinson's disease by regulating NLRP3 pathway through sponging miR-223-3p

Xu, W. G., Zhang, L., Geng, Y., Liu, Y., & Zhang, N. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106614 · Cited by 85 · see citing works

Microglia Polarization, Gene-Environment Interactions and Wnt/β-Catenin Signaling: Emerging Roles of Glia-Neuron and Glia-Stem/Neuroprogenitor Crosstalk for Dopaminergic Neurorestoration in Aged Parkinsonian Brain

L’Episcopo, F., Tirolo, C., Serapide, M. F., Caniglia, S., Testa, N., Leggio, L., Vivarelli, S., Iraci, N., Pluchino, S., & Marchetti, B. (2018) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2018.00012 · Cited by 84 · see citing works

Naringenin Produces Neuroprotection Against LPS-Induced Dopamine Neurotoxicity via the Inhibition of Microglial NLRP3 Inflammasome Activation

Chen, C., Wei, Y.-Z., He, X., Li, D., Wang, G., Li, J.-J., & Zhang, F. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00936 · Cited by 85 · see citing works

Myricetin attenuated MPP+-induced cytotoxicity by anti-oxidation and inhibition of MKK4 and JNK activation in MES23.5 cells

Zhang, K., Ma, Z., Wang, J., Xie, A., & Xie, J. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.04.021 · Cited by 84 · see citing works

Effect of Aspartame on Oxidative Stress and Monoamine Neurotransmitter Levels in Lipopolysaccharide-Treated Mice

Abdel‐Salam, O. M. E., Salem, N. A., & Hussein, J. (2011) · Neurotoxicity Research · doi:10.1007/s12640-011-9264-9 · Cited by 83 · see citing works

DAMPs and neurodegeneration

Thundyil, J., & Lim, K. (2014) · Ageing Research Reviews · doi:10.1016/j.arr.2014.11.003 · Cited by 82 · see citing works

Protective effect of panaxatriol saponins extracted from Panax notoginseng against MPTP-induced neurotoxicity in vivo

Luo, F., Wang, S., Qi, L., Song, J., Lv, T., & Bai, J. (2010) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2010.10.017 · Cited by 81 · see citing works

NNZ-2566 treatment inhibits neuroinflammation and pro-inflammatory cytokine expression induced by experimental penetrating ballistic-like brain injury in rats

Wei, H. H., Lu, X. M., Shear, D. A., Waghray, A., Yao, C., Tortella, F. C., & Dave, J. R. (2009) · Journal of Neuroinflammation · doi:10.1186/1742-2094-6-19 · Cited by 80 · see citing works

The role of T cells in the pathogenesis of Parkinson’s disease

Chen, Z., Chen, S., & Liu, J. (2018) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2018.08.002 · Cited by 78 · see citing works

Targeting Wnt signaling at the neuroimmune interface for dopaminergic neuroprotection/repair in Parkinson's disease

L’Episcopo, F., Tirolo, C., Caniglia, S., Testa, N., Morale, M. C., Serapide, M. F., Pluchino, S., & Marchetti, B. (2014) · Journal of Molecular Cell Biology · doi:10.1093/jmcb/mjt053 · Cited by 80 · see citing works

Rg1 reduces nigral iron levels of MPTP-treated C57BL6 mice by regulating certain iron transport proteins

Wang, J., Xu, H., Yang, H., Du, X., Jiang, H. F., & Xie, J. (2008) · Neurochemistry International · doi:10.1016/j.neuint.2008.10.003 · Cited by 79 · see citing works

Allopregnanolone treatment delays cholesterol accumulation and reduces autophagic/lysosomal dysfunction and inflammation in Npc1−/− mouse brain

Liao, G., Cheung, S., Galeano, J., Ji, A. X., Qin, Q., & Bi, X. (2009) · Brain Research · doi:10.1016/j.brainres.2009.03.027 · Cited by 77 · see citing works

A Nurr1 Agonist Causes Neuroprotection in a Parkinson’s Disease Lesion Model Primed with the Toll-Like Receptor 3 dsRNA Inflammatory Stimulant Poly(I:C)

Smith, G. A., Rocha, E. M., Rooney, T., Barnéoud, P., McLean, J. R., Beagan, J. A., Osborn, T. M., Coimbra, M., Luo, Y., Hallett, P. J., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0121072 · Cited by 78 · see citing works

Journal of Neuroinflammation BioMed Central

Koprich, J. B., Reske-Nielsen, C., Mithal, P., Isacson, O., Mithal, P., & Isacson, O. (2008)

Inflammatory Animal Model for Parkinson's Disease: The Intranigral Injection of LPS Induced the Inflammatory Process along with the Selective Degeneration of Nigrostriatal Dopaminergic Neurons

Machado, A., Herrera, A. J., Venero, J. L., Santiago, M., de Pablos, R. M., Villarán, R. F., Espinosa‐Oliva, A. M., Argüelles, S., Sarmiento, M., Delgado‐Cortés, M. J., et al. (2011) · ISRN Neurology · doi:10.5402/2011/476158 · Cited by 47 · see citing works

Central and systemic IL-1 exacerbates neurodegeneration and motor symptoms in a model of Parkinson’s disease

Pott Godoy, M. C., Tarelli, R., Ferrari, C. C., Sarchi, M. I., & Pitossi, F. J. (2008) · Brain · doi:10.1093/brain/awn101 · Cited by 335 · see citing works

doi:10.5402/2011/476158 Review Article Inflammatory Animal Model for Parkinson’s Disease: The Intranigral Injection of LPS Induced the Inflammatory Process along with the Selective Degeneration of

Neurology, I., & Neurons, N. D. (2013)

Lipopolysaccharide (LPS)-induced dopamine cell loss in culture: roles of tumor necrosis factor-α, interleukin-1β, and nitric oxide

Gayle, D. A., Ling, Z., Tong, C. W., Landers, T. M., Lipton, J. W., & Carvey, P. M. (2002) · Developmental Brain Research · doi:10.1016/s0165-3806(01)00315-7 · Cited by 201 · see citing works